Compare DexCom, Inc. (DXCM) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs United Microelectronics Corp — how do they compare? DexCom, Inc. trades at $84.39 (market cap $31.86B), while United Microelectronics Corp trades at $22.89 (market cap $58.02B). The key difference: United Microelectronics Corp is the larger of the two by market cap, and United Microelectronics Corp pays a 1.76% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and United Microelectronics Corp for 42 Days on average.
| DXCM | UMC | |
|---|---|---|
Market Cap | $31.86B | $58.02B |
Volume | 3,607,070 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $92.34 | $28.02 |
52-Week Low | $54.84 | $7.02 |
Typical Hold Time | 62 Days | 42 Days |
Enterprise Value | $31.32B | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
UMC trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net margin and 21.03% ROE, though revenue growth has moderated from 2022 peaks. Recent earnings beats and a Zacks Strong Buy upgrade (September 17, 2026) highlight positive momentum, while cash flow turned positive in 2025 after two years of outflows.
The stock presents growth potential with expanding AI opportunities and strong 22/28nm demand, but faces risks from semiconductor cycle volatility and competitive pressures. Analyst consensus is mixed with 27% buy ratings versus 20% sell, suggesting cautious optimism amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
